AdaptHealth to sell Diabetes Health unit to Cardinal Health for $235 million
AdaptHealth agreed on July 19, 2026 to sell substantially all assets of its Diabetes Health business to RGH Enterprises, a subsidiary of Cardinal Health, for $235.0 million in cash, subject to a working capital adjustment. The company says the sale lets it redeploy capital to core sleep and respiratory businesses and reduce debt, but it has not yet disclosed the financial effect, which it will cover on its August 4, 2026 earnings call.
Key points
- Purchase price is $235.0 million in cash, with $8.0 million and $18.8 million placed in escrow at closing for price adjustment and indemnification obligations
- Closing requires Hart-Scott-Rodino antitrust clearance and other customary conditions; either party may terminate if closing has not occurred within twelve months, and a $9.4 million termination fee applies in certain antitrust failure case
- AdaptHealth agreed to a four-year non-compete in North America following closing
- Company will discuss financial and guidance effects, including discontinued operations treatment, on its Q2 2026 earnings call on August 4, 2026
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.